Prostate cancer (PCa) is the common cause of death in men. The pathophysiological factors
contributing to PCa are not well known. PCa cells gain a protective mechanism via abnormal …

Androgen deprivation therapy is a common treatment method for metastatic prostate cancer
through lowering androgen levels; however, this therapy frequently leads to the …

BACKGROUND Benign prostatic hyperplasia (BPH) is treated with 5α‐reductase inhibitors
(5ARI). These drugs inhibit the conversion of testosterone to dihydrotestosterone resulting in …

The standard androgen deprivation therapy for advanced prostate cancer includes the use
of bicalutamide, which is a well-known antagonist of androgen receptors. Despite numerous …

Galiellalactone (GL) is a fungal metabolite that presents antitumor and antiinflammatory
activities in vitro and in vivo. Previous studies have shown that GL targets NF-κB and STAT3 …

A Sc (OTf) 3-catalyzed highly diastereoselective one-pot sequential [3+ 3] dipolar
cycloaddition reaction of aldehyde or ketone, N-alkyl hydroxylamine, and spirocyclopropyl …

Prostate cancer is one of the most common seen malignancies and the leading cause of
cancer-related death among men. Given the importance of early diagnosis and treatment, it …

Background Metastatic burden and aggressive behavior determine severity stratification and
guide treatment decisions in prostate cancer (PCa). Monoamine oxidase A (MAOA) may …

Corema (C.) album is a shrub endemic to the Atlantic coast and has been described as
yielding beneficial effects for human health. Nevertheless, studies concerning the bioactivity …

Numerous studies indicate that androgen receptor splice variants (ARVs) play a critical role
in the development of castration-resistant prostate cancer (CRPC), including the resistance …